Dr. Reddy's Eyes 2012 Launch Of Generic Clarinex

By Ben James

Law360, New York (December 29, 2008, 12:00 AM ET) -- Schering Corp., Sepracor Inc. and Dr. Reddy's Laboratories Ltd. have struck settlement deals that should resolve litigation and allow the India-based generics maker to enter the $362 million annual U.S. market for the allergy drug Clarinex in 2012, Dr. Reddy's said.

Dr. Reddy's said the deals resolve all pending suits brought against Dr. Reddy's by Schering and Sepracor over Clarinex in the U.S. District Court for the District of New Jersey, adding that total U.S. sales for all formulations of Clarinex in 2007 were $362 million....
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles